Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
Cancer Biomark ; 40(1): 47-59, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38306024

RESUMEN

BACKGROUND: Docetaxel is a yew compound antitumor agent with accurate antitumor efficacy, but its application is limited due to the high and serious adverse effects, and finding effective combination therapy options is a viable strategy. Immune checkpoint inhibitors have become hotspots in enhancing anti-tumor immunity by blocking immune checkpoint signaling pathways, but their response rate to monotherapy use is not high and the efficacy is minimal. OBJECTIVE: To explore the anti-tumor effects and mechanisms of the combination of PD-1 inhibitors and Docetaxel through in vivo experiments and develop a feasible combination treatment for the therapy of prostate cancer. METHODS: Tumor-bearing mice were subcutaneously injected with 0.1 ml RM-1 cells. Treatment were taken when the tumor growed up to 3 mm, after which the tumor and spleen were removed to test the antitumor effect with Flow cytometric (FACS) analysis, Immunohistochemistry, Western Blot. RESULTS: In this experiment, we found that PD-1 inhibitors combined with Docetaxel had a synergistic effect on mouse prostate cancer, inhibited the growth of prostate cancer, improved survival and reduced adverse reactions, increased spleen and tumor infiltrative CD4+ and CD8+ T cells, especially in group combination with low-dose Docetaxel, and were related to the PI3K/AKT/NFKB-P65/PD-L1 signaling pathway. CONCLUSION: Our study confirms that PD-1 inhibitors in combination with Docetaxel are a viable combination strategy and provide a safe and effective combination option for the clinical treatment of prostate cancer.


Asunto(s)
Antígeno B7-H1 , Docetaxel , Fosfatidilinositol 3-Quinasas , Receptor de Muerte Celular Programada 1 , Neoplasias de la Próstata , Proteínas Proto-Oncogénicas c-akt , Transducción de Señal , Animales , Masculino , Ratones , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Antígeno B7-H1/metabolismo , Antígeno B7-H1/antagonistas & inhibidores , Línea Celular Tumoral , Docetaxel/farmacología , Docetaxel/administración & dosificación , Regulación hacia Abajo/efectos de los fármacos , Sinergismo Farmacológico , Inhibidores de Puntos de Control Inmunológico/farmacología , Fosfatidilinositol 3-Quinasas/efectos de los fármacos , Fosfatidilinositol 3-Quinasas/metabolismo , Receptor de Muerte Celular Programada 1/antagonistas & inhibidores , Receptor de Muerte Celular Programada 1/metabolismo , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/patología , Neoplasias de la Próstata/metabolismo , Proteínas Proto-Oncogénicas c-akt/efectos de los fármacos , Proteínas Proto-Oncogénicas c-akt/metabolismo , Transducción de Señal/efectos de los fármacos , Factor de Transcripción ReIA/efectos de los fármacos , Factor de Transcripción ReIA/metabolismo
2.
PLoS One ; 16(3): e0248043, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33662025

RESUMEN

Abdominal aortic aneurysms (AAA) are associated with systemic inflammation and endothelial dysfunction. We previously reported flow mediated dilatation (FMD) of the brachial artery as a predictor of AAA growth. We hence hypothesised that other physical characteristics of the brachial artery correlate with AAA growth. Using a prospectively cohort of AAA patients, we devised a 'brachial artery relaxation index' (BARI) and examined its role as a biomarker for AAA growth. However, no correlation between BARI and future aneurysm growth was observed (p = 0.45). Therefore, our investigations did not substantiate the hypothesis that other physical characteristics of the brachial artery predicts AAA growth.


Asunto(s)
Aneurisma de la Aorta Abdominal/diagnóstico por imagen , Arteria Braquial/diagnóstico por imagen , Anciano , Femenino , Humanos , Masculino , Pronóstico , Estudios Prospectivos , Ultrasonografía
3.
Sci Rep ; 10(1): 11491, 2020 07 13.
Artículo en Inglés | MEDLINE | ID: mdl-32661264

RESUMEN

Early detection of compromised circulation is essential for postoperative monitoring of free flap. Hourly clinical check-ups such as inspection and palpation still result in a delay in detection. Conversely, optical reflection and temperature measurement are useful alternatives for detecting blood circulation. However, conventional methods that verify ischemia and congestion within a short period have not been reported. In this study, we measured short-term changes in optical reflection and temperature in a rat flap using a wearable flexible sensor probe previously developed in our laboratory. Five ischemia and five congestion groin flap models were measured using a sensor probe and reference devices. Curve fitting was performed on transition signals to evaluate changes in signals and their time constants. The optical reflection signal decreased after venous ligation and increased after arterial ligation. The parameters of the fitted curves indicate a significant difference between congestion and ischemia at p < 0.01 (probability value), which was detected within a few minutes after ligation. However, insufficient significance was observed in the temperature signal. Our method gives supporting information to verify ischemia and congestion, and has the potential to rapidly detect compromised circulation.


Asunto(s)
Isquemia/diagnóstico , Monitoreo Fisiológico/métodos , Enfermedades Vasculares/diagnóstico , Dispositivos Electrónicos Vestibles , Animales , Colgajos Tisulares Libres/patología , Colgajos Tisulares Libres/fisiología , Humanos , Isquemia/sangre , Isquemia/fisiopatología , Microcirugia/efectos adversos , Periodo Posoperatorio , Ratas , Flujo Sanguíneo Regional/fisiología , Temperatura , Enfermedades Vasculares/sangre , Enfermedades Vasculares/fisiopatología
4.
Nanoscale ; 10(39): 18878-18891, 2018 Oct 21.
Artículo en Inglés | MEDLINE | ID: mdl-30277486

RESUMEN

Black phosphorus surface plasmon (BPSP) is a new promising candidate material for electromagnetic field confinement at the subwavelength scale. Here, we theoretically investigated the light confinement, second-order nonlinearity and lifetimes of tunable surface plasmons in nanostructured black phosphorus nanoflakes with superstrates. The grating structure can enhance the local optical field of the fundamental wave (FW) and second harmonic wave (SHW) due to the surface plasmon resonance. Based on the coupled mode theory (CMT), a theoretical model for the nanostructured black phosphorus was established to study the spectrum features of FW. The lifetimes of the plasmonic resonant modes were investigated with the finite difference time domain (FDTD) simulations and CMT. Since the permittivity of black phosphorus depends on its Fermi energy and electron scattering rate, the lifetimes of plasmonic absorption modes are tunable with both the Fermi energy and scattering rate. The intensity, wavelengths and spectral width of BPSP resonance modes and their lifetimes can be precisely controlled with the Fermi energy, scattering rate, side length and refractive index of the superstrate. The sensitivity is described by varying the refractive index of the superstrate such as an aqueous solution. We have introduced a second-order nonlinear source to investigate the SHW of nanostructured black phosphorus. This paper presents the corner/edge energy distribution and the tunable lifetime of BPSP as well as their unprecedented capability of photon manipulation for second-order nonlinearity within the deep subwavelength scale. The configuration and method are useful for research of the absorption, lifetime of light and nonlinear optical processes in black phosphorus-based optoelectronic devices, especially the modulation and sensing applications.

5.
Neuroimage ; 162: 384-397, 2017 11 15.
Artículo en Inglés | MEDLINE | ID: mdl-28887087

RESUMEN

Arterial spin labeling (ASL) MRI is a non-invasive technique for the quantification of cerebral perfusion, and pseudo-continuous arterial spin labeling (PCASL) has been recommended as the standard implementation by a recent consensus of the community. Due to the low spatial resolution of ASL images, perfusion quantification is biased by partial volume effects. Consequently, several partial volume correction (PVEc) methods have been developed to reduce the bias in gray matter (GM) perfusion quantification. The efficacy of these methods relies on both the quality of the ASL data and the accuracy of partial volume estimates. Here we systematically investigate the sensitivity of different PVEc methods to variability in both the ASL data and partial volume estimates using simulated PCASL data and in vivo PCASL data from a reproducibility study. We examined the PVEc methods in two ways: the ability to preserve spatial details and the accuracy of GM perfusion estimation. Judging by the root-mean-square error (RMSE) between simulated and estimated GM CBF, the spatially regularized method was superior in preserving spatial details compared to the linear regression method (RMSE of 1.2 vs 5.1 in simulation of GM CBF with short scale spatial variations). The linear regression method was generally less sensitive than the spatially regularized method to noise in data and errors in the partial volume estimates (RMSE 6.3 vs 23.4 for SNR = 5 simulated data), but this could be attributed to the greater smoothing introduced by the method. Analysis of a healthy cohort dataset indicates that PVEc, using either method, improves the repeatability of perfusion quantification (within-subject coefficient of variation reduced by 5% after PVEc).


Asunto(s)
Encéfalo/diagnóstico por imagen , Imagen por Resonancia Magnética/métodos , Neuroimagen/métodos , Humanos , Aumento de la Imagen/métodos , Interpretación de Imagen Asistida por Computador/métodos , Imagenología Tridimensional/métodos , Marcadores de Spin
6.
J Biol Chem ; 291(26): 13591-607, 2016 Jun 24.
Artículo en Inglés | MEDLINE | ID: mdl-27129260

RESUMEN

One mechanism by which oncoproteins work is through perturbation of cellular maturation; understanding the mechanisms by which this occurs can lead to the development of targeted therapies. EVI1 is a zinc finger oncoprotein involved in the development of acute myeloid leukemia; previous work has shown it to interfere with the maturation of granulocytes from immature precursors. Here we investigate the mechanism by which that occurs, using an immortalized hematopoietic progenitor cell line, EML-C1, as a model system. We document that overexpression of EVI1 abrogates retinoic acid-induced maturation of EML cells into committed myeloid cells, a process that can be documented by the down-regulation of stem cell antigen-1 and acquisition of responsiveness to granulocyte-macrophage colony-stimulating factor. We show that this requires DNA binding capacity of EVI1, suggesting that downstream target genes are involved. We identify the myeloid regulator Cebpa as a target gene and identify two EVI1 binding regions within evolutionarily conserved enhancer elements at +35 and +37 kb relative to the gene. EVI1 can strongly suppress Cebpa transcription, and add-back of Cebpa into EVI1-expressing EML cells partially corrects the block in maturation. We identify the DNA sequences to which EVI1 binds at +35 and +37 kb and show that mutation of one of these releases Cebpa from EVI1-induced suppression. We observe a more complex picture in primary bone marrow cells, where EVI1 suppresses Cebpa in stem cells but not in more committed progenitors. Our data thus identify a regulatory node by which EVI1 contributes to leukemia, and this represents a possible therapeutic target for treatment of EVI1-expressing leukemia.


Asunto(s)
Proteínas Potenciadoras de Unión a CCAAT/metabolismo , Diferenciación Celular , Proteínas de Unión al ADN/metabolismo , Células Madre Hematopoyéticas/metabolismo , Elementos de Respuesta , Factores de Transcripción/metabolismo , Transcripción Genética , Animales , Antígenos Ly/genética , Antígenos Ly/metabolismo , Células de la Médula Ósea/metabolismo , Proteínas Potenciadoras de Unión a CCAAT/genética , Línea Celular , Cricetinae , Proteínas de Unión al ADN/genética , Leucemia/genética , Leucemia/metabolismo , Proteína del Locus del Complejo MDS1 y EV11 , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Ratones , Proto-Oncogenes/genética , Factores de Transcripción/genética
7.
ScientificWorldJournal ; 2014: 284929, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24693233

RESUMEN

We have studied the excitation second-order nonlinearity through a triangular lattice perforated gold film instead of square lattice in many papers. Under the excitation of surface plasmas resonance effect, the second order nonlinearity exists in the noncentrosymmetric split-ring resonators arrays. Reflection of fundamental frequency wave through a triangular lattice perforated gold film is obtained. We also described the second harmonic conversion efficiencies in the second order nonlinear optical process with the spectra. Moreover, the electric field distributions of fundamental frequency above the gold film region are calculated. The light propagation through the holes results in the enhancement of the second order nonlinearity including second harmonic generation as well as the sum (difference) frequency generation.


Asunto(s)
Oro/química , Membranas Artificiales , Modelos Teóricos , Dispersión de Radiación , Resonancia por Plasmón de Superficie/métodos , Simulación por Computador , Luz , Dinámicas no Lineales
8.
PLoS One ; 8(6): e67134, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23826213

RESUMEN

The ecotropic virus integration site 1 (EVI1) transcription factor is associated with human myeloid malignancy of poor prognosis and is overexpressed in 8-10% of adult AML and strikingly up to 27% of pediatric MLL-rearranged leukemias. For the first time, we report comprehensive genomewide EVI1 binding and whole transcriptome gene deregulation in leukemic cells using a combination of ChIP-Seq and RNA-Seq expression profiling. We found disruption of terminal myeloid differentiation and cell cycle regulation to be prominent in EVI-induced leukemogenesis. Specifically, we identified EVI1 directly binds to and downregulates the master myeloid differentiation gene Cebpe and several of its downstream gene targets critical for terminal myeloid differentiation. We also found EVI1 binds to and downregulates Serpinb2 as well as numerous genes involved in the Jak-Stat signaling pathway. Finally, we identified decreased expression of several ATP-dependent P2X purinoreceptors genes involved in apoptosis mechanisms. These findings provide a foundation for future study of potential therapeutic gene targets for EVI1-induced leukemia.


Asunto(s)
Proteínas de Unión al ADN/metabolismo , Leucemia Mieloide Aguda/metabolismo , Factores de Transcripción/metabolismo , Animales , Proteínas Potenciadoras de Unión a CCAAT/metabolismo , Línea Celular , Proteínas de Unión al ADN/genética , Regulación Neoplásica de la Expresión Génica , Humanos , Quinasas Janus/metabolismo , Proteína del Locus del Complejo MDS1 y EV11 , Ratones , Inhibidor 2 de Activador Plasminogénico/metabolismo , Proto-Oncogenes/genética , Factor de Transcripción STAT1/metabolismo , Transducción de Señal , Factores de Transcripción/genética , Transcriptoma
9.
Oncologist ; 17(1): 125-34, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22240540

RESUMEN

BACKGROUND: The immune response of patients who have cancer, who may be receiving immunosuppressive therapy, is generally considered to be decreased. This study aimed to evaluate the immune response of cancer patients to the 2009 influenza A (H1N1) vaccine. PATIENTS AND METHODS: We conducted a prospective single site study comparing the immune response after H1N1 vaccination of healthy controls (group A), patients who had solid tumors and were taking myelosuppressive chemotherapy (group B), patients who had solid tumors and were taking nonmyelosuppressive or no treatment (group C), and patients who had hematologic malignancies (group D). RESULTS: At 2-6 weeks after vaccination, seroconversion was observed in 80.0% of group A (95% confidence interval [CI], 65.0%-89.7%), 72.2% of group B (95% CI, 55.9%-84.3%), 87.0% of group C (95% CI, 72.2%-94.7%), and 75.0% of group D (95% CI, 52.8%-89.2%) (p = NS). The geometric mean titer ratio, that is, geometric mean factor increase in antibody titer after vaccination, was 12.6 (95% CI, 7.9-19.9), 12.7 (95% CI, 7.3-22.1), 23.0 (95% CI, 13.9-38.2), and 12.1 (95% CI, 5.3-27.9) (p = NS), and the seroprotection rates were 95.5% (95% CI, 84.0%-99.6%), 79.0% (95% CI, 63.4%-89.2%), 90.5% (95% CI, 77.4%-96.8%), and 90.0% (95% CI, 71%-98.7%) in the corresponding groups (p = NS). Immune responses were robust regardless of malignancy, or time intervals between the use of myelosuppressive or immunosuppressive medications and vaccination. No participants developed clinical H1N1 infection. CONCLUSION: Cancer patients, whether taking myelosuppressive chemotherapy or not, are able to generate an immune response to the H1N1 vaccine similar to that of healthy controls.


Asunto(s)
Subtipo H1N1 del Virus de la Influenza A/inmunología , Vacunas contra la Influenza/inmunología , Neoplasias/inmunología , Adulto , Anciano , Estudios de Casos y Controles , Femenino , Humanos , Vacunas contra la Influenza/administración & dosificación , Masculino , Persona de Mediana Edad , Neoplasias/tratamiento farmacológico , Estudios Prospectivos
10.
Leuk Lymphoma ; 49(12): 2321-7, 2008 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19052980

RESUMEN

We measured histone deacetylase (HDAC) activity in 17 patients with primary myelofibrosis (PMF); 19 with other myeloproliferative neoplasm (MPN) and 16 normal volunteers. Significantly elevated HDAC levels were shown in patients with PMF compared with other MPN patients and normal volunteers (p<0.05). Sixteen patients with PMF were also studied for correlation between JAK2 mutation status and HDAC levels; no significant correlation was found. We further correlated HDAC levels with clinical features in PMF: there was no correlation with WBC, platelet counts, Hb levels or degree of bone marrow fibrosis, but HDAC levels were correlated to the degree of splenomegaly. This suggests that HDAC may be recruited as essential thrombocythemia or polycythemia vera progresses into myelofibrosis or PMF progresses into more advanced stage. We then used the qRT-PCR cycle threshold (CT) method to study which HDACs were elevated in PMF. The results showed that, in general, Class 1 HDACs were elevated (HDAC1,2,8) except HDAC3, Class II HDACs were depressed (HDAC4,5) except HDAC6 and 10, and Class III HDACs were generally elevated. The current study may form the basis for using HDAC inhibitor in the treatment of patients with PMF and may implicate a possible role of HDAC in the association of pathogenesis of PMF.


Asunto(s)
Histona Desacetilasas/metabolismo , Mielofibrosis Primaria/enzimología , Estudios de Casos y Controles , Células Madre Hematopoyéticas/enzimología , Humanos , Isoenzimas/análisis , Janus Quinasa 2/genética , Mutación , Trastornos Mieloproliferativos/enzimología , Mielofibrosis Primaria/etiología
11.
J Biol Chem ; 281(39): 29357-68, 2006 Sep 29.
Artículo en Inglés | MEDLINE | ID: mdl-16882668

RESUMEN

Calcium-independent phospholipase A(2) (iPLA(2)) plays a pivotal role in phospholipid remodeling and many other biological processes, including inflammation and cancer development. iPLA(2) can be activated by caspase-3 via a proteolytic process in apoptotic cells. In this study we identify novel signaling and functional loops of iPLA(2) activation leading to migration of non-apoptotic human ovarian cancer cells. The extracellular matrix protein, laminin-10/11, but not collagen I, induces integrin- and caspase-3-dependent cleavage and activation of overexpressed and endogenous iPLA(2). The truncated iPLA(2) (amino acids 514-806) generates lysophosphatidic acid and arachidonic acid. Arachidonic acid is important for enhancing cell migration toward laminin-10/11. Lysophosphatidic acid activates Akt that in turn acts in a feedback loop to block the cleavage of poly-(ADP-ribose) polymerase and DNA fragmentation factor as well as prevent apoptosis. By using pharmacological inhibitors, blocking antibodies, and genetic approaches (such as point mutations, dominant negative forms of genes, and siRNAs against specific targets), we show that beta(1), but not beta(4), integrin is involved in iPLA(2) activation and cell migration to laminin-10/11. The role of caspase-3 in iPLA(2) activation and cell migration are supported by several lines of evidence. 1) Point mutation of Asp(513) (a cleavage site of caspase-3 in iPLA(2)) to Ala blocks laminin-10/11-induced cleavage and activation of overexpressed iPLA(2), whereas mutation of Asp(733) to Ala has no such effect, 2) treatment of inhibitors or a small interfering RNA against caspase-3 results in decreased cell migration toward laminin-10/11, and 3) selective caspase-3 inhibitor blocks cleavage of endogenous iPLA(2) induced by laminin-10/11. Importantly, small interfering RNA-mediated down-regulation of endogenous iPLA(2) expression in ovarian carcinoma HEY cells results in decreased migration toward laminin, suggesting that our findings are pathophysiologically important.


Asunto(s)
Apoptosis , Calcio/metabolismo , Caspasa 3/metabolismo , Neoplasias Ováricas/metabolismo , Fosfolipasas A/metabolismo , Movimiento Celular , Activación Enzimática , Femenino , Humanos , Integrinas/metabolismo , Laminina/metabolismo , Lisofosfolípidos/farmacología , Modelos Biológicos , Fosfolipasas A2
12.
Blood ; 107(2): 733-41, 2006 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-16204320

RESUMEN

Myeloid leukemias in AKXD23 mice contain proviral insertions at Evi1, resulting in transcriptional activation. Although Evi1 is clearly involved in leukemia, gene transfer studies in mice with Evi1 fail to cause leukemia, arguing that cooperating events are necessary. We reanalyzed AKXD-23 tumors for cooperating proviral insertion and found that each tumor had a proviral insertion in Sox4, which encodes an HMG-box transcription factor. RNA analysis revealed these insertions cause increased Sox4 expression. Overexpression of Sox4 in 32Dcl3 cells markedly inhibited cytokine-induced granulocyte maturation, as documented by morphologic and mRNA analysis. Sox4-expressing cells had higher levels of transcripts associated with proliferation, including Evi1. Conversely, in leukemic cells that express Sox4 and bear provirally activated Evi1, suppression of Sox4 with short hairpin RNAs resulted in down-regulation of both Sox4 and Evi1. By cotransfection studies, Sox4 is able to transactivate the AKV long terminal repeat, which likely explains how Sox4 transcriptionally up-regulates provirally activated Evi1; however, Sox4 does not appear to regulate the native Evi1 promoter. We propose that Sox4 proviral activation is selected for in the setting of prior proviral activation of Evi1, because it transactivates the relatively weak LTR of AKV leading to higher Evi1 expression and consequent block to differentiation.


Asunto(s)
Proteínas de Unión al ADN/metabolismo , Proteínas del Grupo de Alta Movilidad/metabolismo , Leucemia Mieloide/metabolismo , Provirus , Secuencias Repetidas Terminales , Transactivadores/metabolismo , Factores de Transcripción/metabolismo , Activación Transcripcional , Animales , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/metabolismo , Diferenciación Celular , Proliferación Celular , Citocinas/farmacología , Proteínas de Unión al ADN/antagonistas & inhibidores , Proteínas de Unión al ADN/genética , Regulación hacia Abajo , Perfilación de la Expresión Génica , Granulocitos/citología , Granulocitos/efectos de los fármacos , Granulocitos/metabolismo , Proteínas del Grupo de Alta Movilidad/antagonistas & inhibidores , Proteínas del Grupo de Alta Movilidad/genética , Leucemia Mieloide/genética , Proteína del Locus del Complejo MDS1 y EV11 , Ratones , Análisis de Secuencia por Matrices de Oligonucleótidos , Proto-Oncogenes/genética , ARN Mensajero/análisis , ARN Interferente Pequeño/farmacología , Factores de Transcripción SOXC , Transactivadores/antagonistas & inhibidores , Transactivadores/genética , Factores de Transcripción/antagonistas & inhibidores , Factores de Transcripción/genética , Transfección
13.
Comp Biochem Physiol C Toxicol Pharmacol ; 134(4): 439-50, 2003 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12727293

RESUMEN

The goal of this work was to characterize the roles of mu-calpain in skeletal muscle protein degradation. Three approaches were developed to alter mu-calpain activity in rat myotubes. These included over-expression of antisense mu-calpain (mu-AS), dominant negative mu-calpain (mu-DN) and the antisense 30-kDa calpain subunit (30-AS). Constructs were expressed in rat L8 myotubes, and their effects on protein degradation and on concentrations of intact and/or degraded fodrin, desmin and tropomyosin were examined. An ecdysone-inducible expression system, in which we replaced a constitutively active CMV promoter with a skeletal muscle-specific alpha-actin promoter, was used to drive expression. Cell lines were evaluated by expression of the gene-of-interest following addition of ponasterone A (PA; ecdysone analog) to culture medium. Changes in calpain activity were assessed by evaluating fodrin degradation. 30-AS, which should alter both mu- and m-calpain activities, increased intact fodrin concentration. mu-DN and mu-AS reduced fodrin degradation products. mu-DN reduced total protein degradation by 7.9% (P<0.01) at 24 h and by 10.6% (P<0.01) at 48 h. mu-AS reduced total protein degradation by 6.4% at 24 h (P<0.05). 30-AS reduced total protein degradation by 13.4% (P<0.05) and 7.3% (P<0.05) following 24 and 48 h of PA administration, respectively. We assessed effects of mu-DN, mu-AS and 30-AS on concentrations of desmin and tropomyosin. Inhibition of calpains stabilized desmin, but had no effect on tropomyosin. These data indicate that fodrin and desmin are mu-calpain substrates and that mu-calpain accounts for a small proportion of total protein degradation in muscle cells. Tropomyosin is not degraded by calpain in muscle cells.


Asunto(s)
Calpaína/fisiología , Músculo Esquelético/enzimología , Mioblastos Esqueléticos/enzimología , Mioblastos Esqueléticos/fisiología , Animales , Línea Celular , Regulación Enzimológica de la Expresión Génica/fisiología , Músculo Esquelético/citología , Músculo Esquelético/fisiología , Mioblastos Esqueléticos/citología , Ratas
14.
Int J Biochem Cell Biol ; 35(1): 79-85, 2003 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-12467649

RESUMEN

The goal of this study was to develop an inducible gene expression system to assess functions of specific proteins in differentiated cultured skeletal muscle. We utilized and modified the ecdysone inducible system because others have used this system to express exogenous genes in vitro and in transgenic animals. A limitation of the commercially-available ecdysone system is its constitutive expression in all tissues. Hence, its application in vivo would result in expression of a cloned gene in undifferentiated and differentiated tissues. To target its expression to muscle, we removed the constitutively-active CMV promoter of pVgRXR and replaced it with a skeletal muscle alpha-actin promoter so that the regulatory features of the system would be expressed in differentiated muscle cells. We transfected our newly designed expression system into L8 muscle myoblasts and established stable cell lines via antibiotic selection. We determined that reporter gene activity was induced by ponasterone A in myotubes, a differentiated muscle phenotype, but not in myoblasts (undifferentiated cells). This proved the validity of the concept of an inducible muscle-specific expression system. We then determined that beta-galactosidase expression was dependent upon the dose of ponasterone A and duration of exposure to inducer. This creates potential to regulate both the level of expression and duration of expression of a cloned gene in differentiated muscle.


Asunto(s)
Ecdisterona/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Músculo Esquelético/fisiología , Actinas/efectos de los fármacos , Actinas/genética , Animales , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/genética , Células Cultivadas , Citomegalovirus/genética , Relación Dosis-Respuesta a Droga , Ecdisterona/análogos & derivados , Ingeniería Genética/métodos , Músculo Esquelético/citología , Músculo Esquelético/efectos de los fármacos , Mioblastos/citología , Mioblastos/efectos de los fármacos , Mioblastos/fisiología , Plásmidos/genética , Regiones Promotoras Genéticas , Ratas , Transfección , beta-Galactosidasa/efectos de los fármacos , beta-Galactosidasa/genética , beta-Galactosidasa/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA